FR22C1013I2 - Dihydronaphtyridines et composés apparentés utiles comme inhibiteurs de kinases pour le traitement de maladies prolifératives - Google Patents

Dihydronaphtyridines et composés apparentés utiles comme inhibiteurs de kinases pour le traitement de maladies prolifératives

Info

Publication number
FR22C1013I2
FR22C1013I2 FR22C1013C FR22C1013C FR22C1013I2 FR 22C1013 I2 FR22C1013 I2 FR 22C1013I2 FR 22C1013 C FR22C1013 C FR 22C1013C FR 22C1013 C FR22C1013 C FR 22C1013C FR 22C1013 I2 FR22C1013 I2 FR 22C1013I2
Authority
FR
France
Prior art keywords
dihydronaphtyridines
treatment
kinase inhibitors
compounds useful
related compounds
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
FR22C1013C
Other languages
English (en)
French (fr)
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Deciphera Pharmaceuticals LLC
Original Assignee
Deciphera Pharmaceuticals LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Deciphera Pharmaceuticals LLC filed Critical Deciphera Pharmaceuticals LLC
Publication of FR22C1013I1 publication Critical patent/FR22C1013I1/fr
Application granted granted Critical
Publication of FR22C1013I2 publication Critical patent/FR22C1013I2/fr
Active legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
FR22C1013C 2012-06-07 2022-04-07 Dihydronaphtyridines et composés apparentés utiles comme inhibiteurs de kinases pour le traitement de maladies prolifératives Active FR22C1013I2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP17208408.9A EP3366293B1 (en) 2012-06-07 2012-06-07 Dihydronaphthyridines and related compounds useful as kinase inhibitors for the treatment of proliferative diseases
PCT/US2012/041378 WO2013184119A1 (en) 2012-06-07 2012-06-07 Dihydronaphthyridines and related compounds useful as kinase inhibitors for the treatment of proliferative diseases

Publications (2)

Publication Number Publication Date
FR22C1013I1 FR22C1013I1 (fr) 2022-06-17
FR22C1013I2 true FR22C1013I2 (fr) 2022-12-30

Family

ID=49712374

Family Applications (1)

Application Number Title Priority Date Filing Date
FR22C1013C Active FR22C1013I2 (fr) 2012-06-07 2022-04-07 Dihydronaphtyridines et composés apparentés utiles comme inhibiteurs de kinases pour le traitement de maladies prolifératives

Country Status (28)

Country Link
EP (3) EP3722296A3 (it)
JP (1) JP5883195B2 (it)
KR (1) KR101652229B1 (it)
CN (3) CN110403938A (it)
AU (1) AU2012327210B2 (it)
BR (1) BR112014030577B1 (it)
CA (1) CA2875970C (it)
CY (1) CY1123377T1 (it)
DK (2) DK2858646T3 (it)
ES (2) ES2797252T3 (it)
FR (1) FR22C1013I2 (it)
HR (1) HRP20200864T1 (it)
HU (2) HUE049958T2 (it)
IL (1) IL236110A (it)
LT (2) LT3366293T (it)
LU (1) LUC00253I2 (it)
MX (2) MX392372B (it)
NL (1) NL301169I2 (it)
NO (1) NO2022010I1 (it)
PH (2) PH12018502294B1 (it)
PL (1) PL3366293T3 (it)
PT (2) PT2858646T (it)
RS (1) RS60406B1 (it)
RU (1) RU2664055C2 (it)
SG (1) SG11201408133TA (it)
SI (1) SI3366293T1 (it)
SM (1) SMT202000302T1 (it)
WO (1) WO2013184119A1 (it)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8461179B1 (en) 2012-06-07 2013-06-11 Deciphera Pharmaceuticals, Llc Dihydronaphthyridines and related compounds useful as kinase inhibitors for the treatment of proliferative diseases
MY181020A (en) 2013-03-15 2020-12-16 Sanofi Sa Heteroaryl compounds and uses thereof
TWI647220B (zh) 2013-03-15 2019-01-11 美商西建卡爾有限責任公司 雜芳基化合物及其用途
MA38393B1 (fr) 2014-03-13 2018-11-30 Sanofi Sa Composés hétéroaryle et utilisations associées
MX382436B (es) 2016-01-11 2025-03-13 Merck Patent Gmbh Derivados de quinolin-2-ona.
BR112019025346A2 (pt) * 2017-05-30 2020-06-30 Deciphera Pharmaceuticals, Inc. uso de 1-[4-bromo-5-[1-etil-7-(metilamino)-2-oxo-1,2-dihidro-1,6-naftiridin-3-il]-2-fluorofenil]-3-fenilureia e análogos para o tratamento de cânceres associados a anormalidades genéticas no receptor alfa do fator de crescimento derivado de plaquetas
CN111094286B (zh) * 2017-09-20 2022-07-29 浙江海正药业股份有限公司 1,2-二氢-1,6-萘啶类衍生物、其制备方法及其在医药上的用途
KR102708177B1 (ko) * 2018-01-31 2024-09-23 데시페라 파마슈티칼스, 엘엘씨. 위장관 기질 종양의 치료를 위한 병용 요법
CN118903436A (zh) 2018-01-31 2024-11-08 德西费拉制药有限责任公司 治疗肥大细胞增多症的组合疗法
IL330104A (en) 2019-03-11 2026-08-01 Deciphera Pharmaceuticals Llc Crystalline forms of rifatinib
CN114072148A (zh) 2019-05-03 2022-02-18 金耐特生物制药公司 Raf激酶的抑制剂
HRP20260411T1 (hr) 2019-08-12 2026-05-08 Deciphera Pharmaceuticals, Llc Ripretinib za liječenje gastrointestinalnih stromalnih tumora
US12691108B2 (en) 2019-08-12 2026-07-28 Deciphera Pharmaceuticals, Llc Methods for treating vascular malformations
CN114746096A (zh) * 2019-10-04 2022-07-12 缆图药品公司 使用阿伐替尼治疗嗜酸性粒细胞紊乱
AU2020371727B2 (en) 2019-10-24 2026-01-22 Pierre Fabre Medicament Inhibitors of RAF kinases
FI4084779T3 (fi) 2019-12-30 2024-12-16 Deciphera Pharmaceuticals Llc 1-(4-bromi-5-(1-etyyli-7-(metyyliamino)-2-okso-1,2-dihydro-1,6-naftyridin-3-yyli)-2-fluorifenyyli)-3-fenyyliurean koostumuksia
KR102535840B1 (ko) * 2020-07-31 2023-05-23 (주)파로스아이바이오 2,3,5-치환된 싸이오펜 화합물의 위장관기질종양 예방, 개선 또는 치료 용도
WO2022060996A1 (en) 2020-09-18 2022-03-24 Kinnate Biopharma Inc. Inhibitors of raf kinases
US11377431B2 (en) 2020-10-12 2022-07-05 Kinnate Biopharma Inc. Inhibitors of RAF kinases
CN112625038A (zh) * 2020-12-31 2021-04-09 武汉九州钰民医药科技有限公司 制备瑞普替尼的方法
WO2022162690A1 (en) * 2021-01-28 2022-08-04 Dr. Reddy's Laboratories Limited Process for the preparation of ripretinib and solid state forms thereof
TW202308645A (zh) 2021-04-23 2023-03-01 美商奇奈特生物製藥公司 使用raf抑制劑之癌症治療
JP7825636B2 (ja) 2021-04-23 2026-03-06 ピエール ファーブル メディカモン （ｓ）－ｎ－（３－（２－（（（ｒ）－１－ヒドロキシプロパン－２－イル）アミノ）－６－モルホリノピリジン－４－イル）－４－メチルフェニル）－３－（２，２，２－トリフルオロエチル）ピロリジン－１－カルボキサミドおよびその塩の固体状態での形態
WO2023122322A1 (en) * 2021-12-24 2023-06-29 Teva Pharmaceuticals International Gmbh Improved processes for the preparation of ripretinib
CN114213411B (zh) * 2022-01-24 2023-06-30 成都伊诺达博医药科技有限公司 一种瑞普替尼的合成方法
TW202342055A (zh) 2022-02-03 2023-11-01 美商奇奈特生物製藥公司 Raf激酶抑制劑
US11779572B1 (en) 2022-09-02 2023-10-10 Deciphera Pharmaceuticals, Llc Methods of treating gastrointestinal stromal tumors

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005034869A2 (en) * 2003-10-08 2005-04-21 Irm Llc Compounds and compositions as protein kinase inhibitors
DE102006030524A1 (de) * 2006-07-01 2008-01-03 Koch Transporttechnik Gmbh Verfahren und Vorrichtung zur Beseitigung von lockerem Material auf wellenförmigen Oberflächen gestampfter Kohle für die Verkokung
US8188113B2 (en) 2006-09-14 2012-05-29 Deciphera Pharmaceuticals, Inc. Dihydropyridopyrimidinyl, dihydronaphthyidinyl and related compounds useful as kinase inhibitors for the treatment of proliferative diseases
CN101516379A (zh) * 2006-09-14 2009-08-26 迪赛孚尔制药有限公司 可用于治疗增殖性疾病的激酶抑制剂
EP2076513A1 (en) * 2006-10-20 2009-07-08 Irm Llc Compositions and methods for modulating c-kit and pdgfr receptors
EP2252612B1 (en) * 2008-02-22 2012-03-28 Irm Llc Heterocyclic compounds and compositions as c-kit and pdgfr kinase inhibitors

Also Published As

Publication number Publication date
PT3366293T (pt) 2020-06-18
RU2664055C2 (ru) 2018-08-14
HUS2200017I1 (hu) 2022-06-28
PH12018502294B1 (en) 2024-02-28
PT2858646T (pt) 2018-03-27
NL301169I2 (nl) 2026-03-02
WO2013184119A1 (en) 2013-12-12
ES2663605T3 (es) 2018-04-16
DK3366293T3 (da) 2020-06-15
EP2858646B1 (en) 2017-12-20
HRP20200864T1 (hr) 2020-08-21
LUC00253I2 (it) 2025-03-04
ES2797252T3 (es) 2020-12-01
AU2012327210B2 (en) 2016-07-28
KR101652229B1 (ko) 2016-08-30
LTPA2022008I1 (it) 2022-05-25
CN104902895B (zh) 2019-03-29
EP3722296A2 (en) 2020-10-14
EP3722296A3 (en) 2020-10-21
MX2014015024A (es) 2015-07-06
KR20150053894A (ko) 2015-05-19
EP2858646A1 (en) 2015-04-15
FR22C1013I1 (fr) 2022-06-17
NO2022010I1 (no) 2022-04-07
SI3366293T1 (sl) 2020-08-31
MX392372B (es) 2025-03-24
BR112014030577A8 (pt) 2018-10-23
BR112014030577B1 (pt) 2022-02-08
CN110403938A (zh) 2019-11-05
IL236110A (en) 2016-11-30
PH12014502757B1 (en) 2015-03-02
CY1123377T1 (el) 2021-12-31
CA2875970C (en) 2017-07-04
CN104902895A (zh) 2015-09-09
EP3366293B1 (en) 2020-03-11
LTC3366293I2 (it) 2024-11-25
MX2020005712A (es) 2022-05-17
AU2012327210A1 (en) 2014-01-09
LT3366293T (lt) 2020-07-10
JP2015520186A (ja) 2015-07-16
RS60406B1 (sr) 2020-07-31
SMT202000302T1 (it) 2020-07-08
PL3366293T3 (pl) 2020-09-21
HK1209345A1 (en) 2016-04-01
SG11201408133TA (en) 2015-01-29
CA2875970A1 (en) 2013-12-12
IL236110A0 (en) 2015-01-29
PH12018502294A1 (en) 2020-11-04
JP5883195B2 (ja) 2016-03-09
EP3366293A1 (en) 2018-08-29
DK2858646T3 (en) 2018-03-19
MX372814B (es) 2020-07-03
RU2014153920A (ru) 2016-07-27
PH12014502757A1 (en) 2015-03-02
CN110433162A (zh) 2019-11-12
EP2858646A4 (en) 2015-09-02
HUE049958T2 (hu) 2020-11-30

Similar Documents

Publication Publication Date Title
FR22C1013I1 (fr) Dihydronaphtyridines et composés apparentés utiles comme inhibiteurs de kinases pour le traitement de maladies prolifératives
FR19C1062I2 (fr) Derives macrocycliques pour le traitement de maladies proliferatives
IL283943A (en) Use of pyrazolopyrimidine derivatives for the treatment of pi3k related disorders
IL267609B (en) Beta protein inhibitors in combination with Janus kinase inhibitors for the treatment of proliferative diseases
AP3847A (en) Substituted benzylindazoles for use as bub1 kinase inhibitors in the treatment of hyperproliferative diseases
PT3418281T (pt) Pirazolo[1,5-a]pirimidinas úteis como inibidores da quinase atr para o tratamento de doenças de cancro
EP2925740A4 (en) INHIBITORS OF BRUTON TYROSINE KINASE
IL244492A0 (en) Broton tyrosine kinase inhibitors
EP2988743A4 (en) Heterocyclic compounds for the treatment of diseases
EP2852579A4 (en) PYRIMIDINE COMPOUNDS FOR CANCER TREATMENT
EP2766352A4 (en) INDAZOLE COMPOUNDS AS KINASE INHIBITORS AND METHOD OF TREATING CANCER WITH THE SAME
EP2858500A4 (en) BRUTON TYROSINE KINASE HEMMER
EP2976340A4 (en) CYCLOALKYLNITRILPYRAZOLOPYRIDONE AS JANUSKINASEINHIBITORS
IL282112A (en) Diagnostic markers for treating cell proliferative disorders with telomerase inhibitors
ME03078B (me) Derivati sulfonil piperidina i njihova upotreba za lečenje bolesti posredovanih preko prokineтicina
EP2773342A4 (en) COMPOSITIONS FOR THE TREATMENT OF VIRUS DISEASES
LT2928477T (lt) Telomerazės inhibitoriaus imetelstato panaudojimas mielofibrozės gydymui
PL2880035T3 (pl) Nowe związki pirolopirymidynowe jako inhibitory kinaz białkowych
EP2968321A4 (en) COMPOUNDS FOR THE TREATMENT OF FIBROSIS DISEASES
EP2863748A4 (en) 1,2,4-triazine-6-CARBOXAMIDKINASEINHIBITOREN
EP2833886A4 (en) SUBSTITUTED CHINOLINES AS AN INHIBITORS OF BRUTONTYROSINKINASE
EP2825173A4 (en) CALMODULIN INHIBITORS FOR THE TREATMENT OF RIBOSOMAL DISEASES AND RIBOSOMAPATHIES
EP3316887A4 (en) GLS1-INHIBITOR TO TREAT DISEASES
EP2922534A4 (en) METHOD AND COMPOSITIONS FOR TREATING NEURODEEGENERATIVE DISEASES
EP2895504A4 (en) TRPV3 AGONISTS FOR THE TREATMENT OF SKIN DISEASES